There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viveve Medical Inc (VIVE) and Epizyme (EPZM) with bullish sentiments.
Viveve Medical Inc (VIVE)
In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Viveve Medical Inc, with a price target of $6. The company’s shares closed yesterday at $1.17, close to its 52-week low of $0.93.
Vendetti commented:
“Market open, VIVE reported preliminary 4Q18 revenue that was slightly above both our estimate and consensus. However, the company also introduced full-year 2019 revenue guidance that was slightly below both our estimate and consensus. VIVE announced a strategic restructuring that is expected to reduce its workforce by 36% in order to decrease operating costs. Based on its recent capital raise and strategic realignment plan, we believe VIVE has sufficient cash to fund operations through 1Q20. The company plans to report full 4Q18 results in March 2019.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 3.7% and a 50.0% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Restoration Robotics Inc, Xtant Medical Holdings, and Ra Medical Systems Inc.
Currently, the analyst consensus on Viveve Medical Inc is a Strong Buy with an average price target of $4.50, which is a 284.6% upside from current levels. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $4 price target.
See today’s analyst top recommended stocks >>
Epizyme (EPZM)
Roth Capital analyst Jotin Marango maintained a Buy rating on Epizyme today and set a price target of $18. The company’s shares closed yesterday at $9.64.
According to TipRanks.com, Marango has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.1% and a 29.7% success rate. Marango covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Actinium Pharmaceuticals, and Aptevo Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $20.33 average price target, representing an 110.9% upside. In a report issued on January 7, Leerink Partners also upgraded the stock to Buy with a $12 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
